Browse COL5A2

Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF01410 Fibrillar collagen C-terminal domain
PF01391 Collagen triple helix repeat (20 copies)
PF00093 von Willebrand factor type C domain
Function

Type V collagen is a member of group I collagen (fibrillar forming collagen). It is a minor connective tissue component of nearly ubiquitous distribution. Type V collagen binds to DNA, heparan sulfate, thrombospondin, heparin, and insulin. Type V collagen is a key determinant in the assembly of tissue-specific matrices (By similarity).

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001654 eye development
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0007369 gastrulation
GO:0007423 sensory organ development
GO:0007492 endoderm development
GO:0010470 regulation of gastrulation
GO:0030198 extracellular matrix organization
GO:0030199 collagen fibril organization
GO:0030574 collagen catabolic process
GO:0032963 collagen metabolic process
GO:0035987 endodermal cell differentiation
GO:0043062 extracellular structure organization
GO:0043200 response to amino acid
GO:0043588 skin development
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0045992 negative regulation of embryonic development
GO:0045995 regulation of embryonic development
GO:0048592 eye morphogenesis
GO:0071229 cellular response to acid chemical
GO:0071230 cellular response to amino acid stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0090596 sensory organ morphogenesis
GO:1903224 regulation of endodermal cell differentiation
GO:1903225 negative regulation of endodermal cell differentiation
GO:2000542 negative regulation of gastrulation
Molecular Function GO:0005201 extracellular matrix structural constituent
GO:0046332 SMAD binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005581 collagen trimer
GO:0005583 fibrillar collagen trimer
GO:0005588 collagen type V trimer
GO:0005788 endoplasmic reticulum lumen
GO:0044420 extracellular matrix component
GO:0098643 banded collagen fibril
GO:0098644 complex of collagen trimers
> KEGG and Reactome Pathway
 
KEGG hsa04974 Protein digestion and absorption
Reactome R-HSA-2022090: Assembly of collagen fibrils and other multimeric structures
R-HSA-1650814: Collagen biosynthesis and modifying enzymes
R-HSA-8948216: Collagen chain trimerization
R-HSA-1474290: Collagen formation
R-HSA-1474244: Extracellular matrix organization
Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between COL5A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of COL5A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of COL5A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.50.02
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.3120.302
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9020.581
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9130.0889
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2240.674
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5150.893
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2280.75
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5880.77
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.0390.657
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8860.626
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.5580.29
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.230.26
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of COL5A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.49.6-2.21
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.411.9-4.50.713
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.817.66.20.709
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.827.33.51
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382726.311.115.20.209
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221327.37.719.60.22
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16142514.310.70.657
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of COL5A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of COL5A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by COL5A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of COL5A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of COL5A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between COL5A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCOL5A2
Namecollagen, type V, alpha 2
Aliases AB collagen; collagen, fetal membrane, A polypeptide; type V preprocollagen alpha 2 chain; Collagen alpha-2( ......
Chromosomal Location2q14-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting COL5A2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.